Faes Farma S.A. Logo

Faes Farma S.A.

Develops and markets pharmaceuticals, like antihistamines, and animal nutrition products globally.

FAE | MC

Overview

Corporate Details

ISIN(s):
ES0134950F36
LEI:
959800FXZQY7U3P1G969
Country:
Spain
Address:
AVENIDA AUTONOMIA, 10-, 48940 Leioa
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Faes Farma S.A. is an international pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceuticals and animal nutrition products. With a history of over 90 years, the company operates two main business lines. The pharmaceutical division focuses on therapeutic areas such as allergies, gastroenterology, and immunology, with key proprietary molecules including the antihistamine Bilastine and Vitamin D treatment Calcifediol. The animal nutrition division provides specialized feeds and nutritional solutions, particularly for swine, through brands like Ingaso Farm and Tecnovit. The company emphasizes innovation through significant R&D investment and has a global presence with direct commercial operations across Europe, Latin America, Africa, and the Middle East.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-16 00:00
Post-Annual General Meeting Information
Acuerdo Junta Extraordinaria de Accionistas
Spanish 115.9 KB
2025-06-25 00:00
Post-Annual General Meeting Information
Aspectos relevantes de la Junta de Accionistas 2025
Spanish 159.0 KB
2025-06-25 00:00
Investor Presentation
Presentación Junta de Accionistas 2025
Spanish 4.2 MB
2025-06-11 00:00
Pre-Annual General Meeting Information
Junta General Extraordinaria de Accionistas
Spanish 167.3 KB
2025-05-19 15:51
Pre-Annual General Meeting Information
Convocatoria de la Junta General de Accionistas de 2025
Spanish 180.2 KB
2025-05-19 00:00
Pre-Annual General Meeting Information
Convocatoria de la Junta General de Accionistas de 2025
Spanish 180.2 KB
2025-05-06 08:25
Investor Presentation
Informe de negocio del primer trimestre de 2025
Spanish 1.7 MB
2025-04-29 16:08
Report Publication Announcement
Faes Farma anuncia la celebración de un webcast para presentar los resultados d…
Spanish 65.2 KB
2025-04-22 11:39
Investor Presentation
Presentación Capital Markets Day 2025
Spanish 4.7 MB
2025-04-22 09:56
Investor Presentation
La Sociedad comunica que hoy celebrará su Capital Markets Day para presentar el…
Spanish 55.7 KB
2025-03-25 18:09
M&A Activity
Faes Farma S.A. ha suscrito un contrato para la adquisición de Laboratorios Edo…
Spanish 67.7 KB
2025-02-28 07:55
Investor Presentation
Informe de negocio y resultados 2024
Spanish 1.2 MB
2025-02-28 07:52
Major Shareholding Notification
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
Spanish 426.0 KB
2025-02-28 07:51
Remuneration Information
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
Spanish 213.3 KB
2025-02-28 00:00
Annual / Quarterly Financial Statement
Spanish 12.1 MB

Automate Your Workflow. Get a real-time feed of all Faes Farma S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Faes Farma S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Faes Farma S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Alpha Cognition Inc. Logo
Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.
United States of America ACOG
Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea 196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America ALMS
Alvotech Logo
Develops and manufactures affordable biosimilar medicines for patients worldwide.
United States of America ALVO
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden ALZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.